Aljian Capital Management LLC Has $228,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Aljian Capital Management LLC decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,705 shares of the life sciences company’s stock after selling 275 shares during the quarter. Aljian Capital Management LLC’s holdings in Illumina were worth $228,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new position in Illumina during the fourth quarter valued at approximately $32,000. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. Private Trust Co. NA lifted its stake in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in shares of Illumina in the 3rd quarter valued at $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ILMN. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Morgan Stanley cut their target price on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Finally, HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Stock Up 2.9 %

Illumina stock opened at $103.57 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market cap of $16.43 billion, a PE ratio of -13.49 and a beta of 1.10. Illumina, Inc. has a fifty-two week low of $99.35 and a fifty-two week high of $156.66. The firm’s 50-day simple moving average is $134.32 and its 200 day simple moving average is $135.12.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Research analysts predict that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.